Second line trastuzumab emtansine following horizontal dual blockade in a real-life setting.
Her-2 positive
breast cancer
metastatic
pertuzumab
trastuzumab emtansine
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
02 Jun 2020
02 Jun 2020
Historique:
received:
14
03
2020
accepted:
27
04
2020
entrez:
18
6
2020
pubmed:
18
6
2020
medline:
18
6
2020
Statut:
epublish
Résumé
Despite relevant medical advancements, metastatic breast cancer remains an uncurable disease. HER2 signaling conditions tumor behavior and treatment strategies of HER2 expressing breast cancer. Cancer treatment guidelines uniformly identify dual blockade with pertuzumab and trastuzumab plus a taxane as best first line and trastuzumab emtansine as preferred second line choice. However, there is no prospectively designed available study focusing on the sequence and outcomes of patients treated with T-DM1 following the triplet. In the following report, data concerning a wide series of patients treated in a real-life setting are presented. Results obtained in terms of response and median progression free survival suggests a significant role for T-DM1 in disease control of metastatic HER2 expressing breast cancer.
Identifiants
pubmed: 32547706
doi: 10.18632/oncotarget.27603
pii: 27603
pmc: PMC7275781
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2083-2091Informations de copyright
Copyright: © 2020 Del Prete et al.
Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST No one.
Références
Breast Cancer. 2019 Jul;26(4):492-498
pubmed: 30737616
J Clin Oncol. 2014 Sep 1;32(25):2750-7
pubmed: 25024070
J Clin Oncol. 2016 Oct 10;34(29):3511-3517
pubmed: 27298406
Oncotarget. 2017 Mar 18;8(38):64481-64489
pubmed: 28969087
Breast Care (Basel). 2018 Aug;13(4):277-283
pubmed: 30319330
Cancers (Basel). 2018 Dec 21;11(1):
pubmed: 30577662
Future Oncol. 2017 Dec;13(30):2791-2797
pubmed: 29182361
Cancer Res. 2008 Nov 15;68(22):9280-90
pubmed: 19010901
Expert Opin Pharmacother. 2019 Jan;20(1):5-9
pubmed: 30396301
J Clin Oncol. 2018 Sep 10;36(26):2736-2740
pubmed: 29939838
Cancer Sci. 2018 Oct;109(10):3305-3315
pubmed: 30076657
Oncotarget. 2017 May 25;8(34):56921-56931
pubmed: 28915642
N Engl J Med. 2020 Feb 13;382(7):610-621
pubmed: 31825192
Breast Cancer Res Treat. 2016 Jun;157(2):363-371
pubmed: 27155668
Clin Cancer Res. 2014 Sep 1;20(17):4436-41
pubmed: 24879797
Oncotarget. 2016 Sep 27;7(39):64431-64446
pubmed: 26824988
Prz Menopauzalny. 2015 Sep;14(3):173-7
pubmed: 26528105
Oncotarget. 2017 Nov 1;8(60):102458-102467
pubmed: 29254261
N Engl J Med. 2019 Feb 14;380(7):617-628
pubmed: 30516102
N Engl J Med. 2012 Jan 12;366(2):109-19
pubmed: 22149875
Clin Breast Cancer. 2020 Apr;20(2):e181-e187
pubmed: 31735691
Ann Oncol. 2018 Aug 1;29(8):1634-1657
pubmed: 30032243
Breast Cancer Res Treat. 2019 Jul;176(1):227-234
pubmed: 30977027
N Engl J Med. 2012 Nov 8;367(19):1783-91
pubmed: 23020162
Front Oncol. 2018 Apr 03;8:89
pubmed: 29670855
PLoS One. 2015 Jul 15;10(7):e0119565
pubmed: 26177501
Breast Cancer (Auckl). 2019 Oct 09;13:1178223419879429
pubmed: 31636482